ZyVersa Therapeutics Targets $70 Billion Market in Innovative Biotech Breakthrough 🚀
Discover how ZyVersa Therapeutics, led by CEO Stephen C. Glover, is aiming to capture a massive $70 billion opportunity in the biotech industry. Learn about their latest clinical advancements and growth potential.
About this video
Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. was recently a guest on Benzinga’s All-Access.
ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs for underserved patients with renal and inflammatory diseases. The company is currently advancing a therapeutic pipeline with multiple programs built around its two proprietary technologies – VAR 200 and IC 100.
The technologies could represent a leap forward in the treatment of several diseases.
ZyVersa is a clinical-stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop transformative drugs for underserved patients with renal and inflammatory diseases. The company is currently advancing a therapeutic pipeline with multiple programs built around its two proprietary technologies – VAR 200 and IC 100.
The technologies could represent a leap forward in the treatment of several diseases.
Video Information
Views
960
Total views since publication
Duration
13:34
Video length
Published
Dec 22, 2023
Release date
About the Channel
Related Trending Topics
LIVE TRENDSThis video may be related to current global trending topics. Click any trend to explore more videos about what's hot right now!
THIS VIDEO IS TRENDING!
This video is currently trending in Algeria under the topic 'g'.